athenahealth, Inc. ATHN
Elliott offers $160/share cash for athenahealth — a 27% premium valuing the company at ~$6.9bn — arguing chronic execution failures make going private the only path to realizing its HCIT potential.
Thesis
Elliott Management, owner of 8.9% of athenahealth, proposes a $160-per-share all-cash take-private valuing the company at ~$6.9 billion — a 27% premium to the current price and ~50% above the pre-13D level. After a year of private engagement, Elliott concludes athenahealth's public-market performance cannot be fixed: the stock has underperformed the NASDAQ by 82% over five years, operating margins have stalled at 14% versus a 30% long-term target, five CFOs have cycled through in four years, and management has repeatedly missed bookings and hospital-implementation guidance. The board refused Elliott's private November 2017 acquisition approach. Drawing on $35bn AUM and a track record of tech take-privates including BMC Software, Quest, SonicWall and Gigamon, Elliott argues the private market is the only setting where athenahealth can fix execution and pursue its mission without quarterly distraction.
SCQA
athenahealth is a differentiated Healthcare IT disruptor with a cloud-based platform envied across the industry, but as a public company its stock has underperformed the NASDAQ by 82% over five years despite a large and attractive market opportunity.
Chronic execution failures — five CFOs in four years, 14% operating margins versus a 30% target, and repeatedly missed bookings and hospital-implementation guidance — plus the board's refusal to engage with Elliott's November 2017 private approach, signal these issues cannot be resolved publicly.
Elliott offers $160 per share in cash for 100% of athenahealth — an enterprise value of ~$6.9 billion — with committed bank financing and co-investor equity, asking the board to sign an NDA and open a three-week confirmatory diligence to finalize the deal.
The $160 all-cash bid represents a 27% premium to the current stock price and ~50% to the pre-13D level, with Elliott indicating that private diligence could substantially improve upon this valuation.
The three reasons
- 1
athenahealth TSR lagged NASDAQ by 82% over five years despite a differentiated HCIT product
- 2
Five CFOs in four years and 14% margins vs 30% target show execution cannot be fixed publicly
- 3
$160 cash offer delivers a 27% premium after the board refused private take-private overtures
Primary demands
- Accept Elliott's $160 per share all-cash take-private offer
- Enter NDA and open confirmatory diligence immediately
- Explore strategic alternatives rather than continuing as a standalone public company
- Hire an empowered operations-minded president and a permanent CFO
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Elliott take-private of Novell
- Elliott take-private of BMC Software
- Elliott take-private of Quest Software
- Elliott take-private of SonicWall
- Elliott take-private of Gigamon
- Elliott private investments in Metrologic, MSC Software, E2open, Mitchell International, ASG Technologies
Notable slides (3)
Notes
Formal public take-private bid letter (known as the 'bear hug' letter) from Jesse Cohn of Elliott to athenahealth board, following a year of private engagement and a November 2017 private acquisition approach rebuffed by the board. Tone is notably collaborative toward CEO Jonathan Bush ('Jonathan's vision') despite a harshly critical operational diagnosis. No valuation framework shown — price is framed purely as a premium. Single TSR peer-gap table on p3 is the only chart. Letter form; not a deck. Campaign ultimately led to the $5.7bn Veritas/Evergreen take-private deal later in 2018 — outcome left as 'unknown' per extraction guidance.